Cargando…
Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2
SARS-CoV-2 is a newly emergent coronavirus, which has adversely impacted human health and has led to the COVID-19 pandemic. There is an unmet need to develop therapies against SARS-CoV-2 due to its severity and lack of treatment options. A promising approach to combat COVID-19 is through the neutral...
Autores principales: | Dong, Jianbo, Huang, Betty, Wang, Bo, Titong, Allison, Gallolu Kankanamalage, Sachith, Jia, Zhejun, Wright, Meredith, Parthasarathy, Pannaga, Liu, Yue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576208/ https://www.ncbi.nlm.nih.gov/pubmed/33082473 http://dx.doi.org/10.1038/s41598-020-74761-y |
Ejemplares similares
-
Author Correction: Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2
por: Dong, Jianbo, et al.
Publicado: (2021) -
Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity
por: Dong, Jianbo, et al.
Publicado: (2020) -
First-in-class trispecific VHH-Fc based antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 and variants
por: Titong, Allison, et al.
Publicado: (2022) -
Optimization of therapeutic antibodies
por: Wang, Bo, et al.
Publicado: (2021) -
Biological activity validation of a computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action
por: Cai, Wenyan, et al.
Publicado: (2021)